** Shares of Cidara Therapeutics CDTX.O edge lower after hours as co looks to capitalize on big pop in its stock to raise equity
** CDTX shares soared ~114% to close at $44.95, nearly 4-yr high, after co early Mon announced positive topline results from Phase II trial for CD388, a non-vaccine preventative of seasonal influenza
** Co said study met primary and secondary efficacy endpoints for all dose groups
** After the bell, San Diego-based firm commenced $250 mln stock offering
** JP Morgan, Morgan Stanley, Guggenheim and Cantor are jt bookrunners
** Cidara has ~13 mln shares outstanding for current market cap of roughly $580 mln, per recent 10-Q filing
** Through Fri close, CDTX shares had lost ~22% in 2025
** All 7 analysts are bullish on CDTX with median PT of $56.50, up from $40 a month ago, latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。